<?xml version="1.0" encoding="UTF-8"?>
<p id="p0190">Another promising drug is chloroquine or its analog, hydroxychloroquine. It was reported that these two drugs may inhibit viral entry by affecting PH dependent endocytosis, and they may also affect viral glycosylation by inhibiting glycosyl-transferases [
 <xref rid="bib113" ref-type="bibr">113</xref>]. They were approved to treat or prevent malaria, as well as rheumatoid arthritis, or systemic lupus erythematosus etc. Moreover, hydroxychloroquine showed fewer side effects than chloroquine [
 <xref rid="bib114" ref-type="bibr">114</xref>]. Several clinical studies on hydroxychloroquine and chloroquine provided fairly satisfying results, better trial designing would be needed to further confirm the therapeutic effectiveness [
 <xref rid="bib115" ref-type="bibr">115</xref>]. Besides of these medications, lopinavir/ritonavir, interferons, as well as the Chinese medicine formulate were also recommended by China for treatment of COVID-19 [
 <xref rid="bib116" ref-type="bibr">116</xref>].
</p>
